Logo

Samsung Bioepis Reports Real-World Data of Benepali (biosimilar- etanercept) in Patients with Psoriasis at EADV 2019

Share this

Samsung Bioepis Reports Real-World Data of Benepali (biosimilar- etanercept) in Patients with Psoriasis at EADV 2019

Shots:

  • The study enrolled BADBIR-registered patient treated with Benepali from Jan 01- 2016 to Sept 01- 2018. BADBIR is a UK and Ireland observational study assessing long-term safety of biologic treatments for psoriasis while Samsung Bioepis participated in it since May 2016
  • The mean disease duration was 22.6 yrs.- PASI and DLQI scores 11.6 and 13.1 respectively- median treatment period 14.1 months. In 48 patients with PASI score at baseline and 6 mos. PASI < 10 (N=20- mean PASI 3.2) no increment after 6 mos. and PASI ≥ 10 (N=28- mean PASI 15.7) reduced after 6 mos. (mean PASI 5.0)
  • Benepali (biosimilar- etanercept) referencing Enbrel is an anti-TNF biosimilar approved by EC in Jan 2016- for moderate to severe RA- JIA- PsA- axSpA  (ankylosing spondylitis and non-radiographic axial spondyloarthritis)- and plaque psoriasis and is available in 25 countries in EU plus most prescribed across France- Germany- Italy- Spain- and the UK combined

Click here to­ read full press release/ article 

 Ref: Samsung Bioepis | Image: Samsung Bioepis


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions